A recombinant virus comprising BPI gene and a pharmaceutical composition containing the same and uses thereof

Abstract

The present invention discloses a recombinant virus, which comprises a viral vector, and a gene construct selected from the following: 1) a human BPI gene or a functional fragment gene thereof, or a degenerate Sequence thereof, and 2) a chimeric gene comprising a human BPI gene or a functional fragment gene thereof, or a degenerate Sequence thereof, wherein the chimeric gene further comprises a Fc constant region gene or its allelic gene of a heavy chain of a human immunoglobulin in the 3' end of the human BPI gene or the functional fragment gene thereof. This invention also discloses the use of the gene construct comprising the human BPI gene or functional fragment gene thereof in the preparation of the pharmaceutical composition of gene therapy of the GNB and / or GNB like pathogen infection in Mammal. The present invention further provides a gene therapy method of the GNB and / or GNB like pathogen infection using the recombinant virus or the pharmaceutical composition.

Description

field of invention [0001] The invention relates to the field of gene therapy for diseases infected by Gram-negative bacteria (GNB) and / or GNB-like pathogens in mammals. Specifically, the present invention relates to a recombinant virus comprising a viral vector and a gene construct selected from the group consisting of: 1) a human BPI gene or a functional fragment gene thereof, or a degenerate sequence thereof; and 2) a human BPI gene or Its functional fragment gene, or a chimeric gene of its degenerate sequence, wherein the 3' end of the human BPI gene or its functional fragment gene is further connected with the human immunoglobulin heavy chain constant region Fc gene or its allelic gene. The present invention also relates to the use of the gene construct containing the human BPI gene or its functional fragment gene for the preparation of a pharmaceutical composition for gene therapy of mammalian GNB and / or GNB-like pathogen infection diseases. The present invention also re...

AI Technical Summary

Problems solved by technology

[0009] Non-viral vectors are safe, but the efficiency of gene transfer is low; with the development of new high-efficiency non-viral vector technology and materials (such as targeting vectors, nanocarriers, etc.), the application of such vectors in gene therapy will become more and more More and more [Manfred, et al. DDT, 7(8): 479 (2002)] [Molas, et al. Curr Gene Ther. 3: 468 (2003)]

[0010] Since Dr. Anderson, an American scientist, and others conducted the first clinical trial of human gene therapy in 1990, according to the statistics of the Recombinant DNA Advisory Committee in the United States, as of March 2004, there have been 619 clinical trials of gene therapy. Involves the prevention and treatment of malignant tumors, genetic diseases, cardiovascular diseases, autoimmune diseases, neuroendocrine system diseases and AIDS, but there is no report on gene therapy for bacterial infection diseases [http: / / www4.od.nih.gov / oba / rac / protocol.pdf]

Images